Gens & Associates 2020 Survey Reflects End-to-end RIM Approach and Veeva Innovation

This year’s Gens & Associates World Class RIM Survey, which gathered input from more than 60 life sciences companies, highlighted a preference for end-to-end RIM on a single platform. About 56% of survey respondents indicated that they were highly likely to use a single platform solution for most of their RIM capabilities, while others said that they’ll investigate that approach over the next few years. Steve Gens, managing partner at Gens & Associates, explains, “Most organizations are in the process of simplifying their regulatory solutions and end-to-end processes. This takes out a lot of the complexity, increases information throughput between functions, and supports a more efficient and timely process.”

Respondents also ranked Veeva first among 20+ software providers on the survey’s Innovation Index. About 82% of survey respondents indicated that Veeva is pushing the industry forward compared to an average of 31% for all other providers.

In addition, Gens & Associates asked participants about connecting RIM solutions to other functional domains including clinical, quality, and safety. These are critical junctures when tackling complex, cross-functional business processes like change control or variation management. In the survey, only 9% of participants indicated that they had an existing connection between RIM and clinical eTMF, and only 17% had a link between RIM and the product change control process. In most cases, respondents described the efficiency of these connections as quite poor, except for the study’s top performers.

If you’re interested in participating in the latest Gens & Associates global COVID-19 Regulatory Impact Pulse survey, please visit this link before October 16, 2020 to learn more.